Welcome!

News Feed Item

Skystar Bio-Pharmaceutical Reports First Quarter Fiscal Year 2014 Financial Results

Revenue of $6.8 Million; Net Income $1 Million; $0.13 Fully Diluted EPS; Conference Call to Be Held Friday, May 16, 2014 at 7:45 AM ET

XI'AN, CHINA -- (Marketwired) -- 05/15/14 -- Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited first quarter fiscal year 2014 earnings, for the period ended March 31, 2014.
First Quarter 2014 Summary

  • Revenue increase 23.5% YoY to $6.8 million as follows:
    • Veterinary medicines totaled $4.8 million, up 40.6% YoY
    • Pro-biotic micro-organism products totaled $1.5 million, decreasing 8.8% YoY
    • Feed additives totaled $0.3 million, increasing 15.5% YoY
    • Veterinary vaccines totaled $0.1 million, increasing 4.1% YoY
  • Gross Profit of $2.8 million increased 8.6% for the first three months of fiscal 2014 YoY
  • Gross Margin of 41.3% for the first three months of fiscal 2014, compared to 47% in the prior 2013 period
  • Net Income of $1 million or $0.13 per fully diluted share, as compared with $0.7 million or $0.09 fully diluted share YoY

Management's Comments
Mr. Weibing Lu, Chairman and Chief Executive Officer of Skystar, commented, "Skystar is pleased with unaudited first quarter results seeing increases in both year over year top and bottom line profitability. Skystar's revenue growth was driven by Veterinary medicine which grew 40% year over year with solid contributions coming from Skystar's other segments. The increased utilization rates for Skystar's veterinary medication production facility were realized following the receipt of more product permits from the Ministry of Agriculture. Skystar's YoY gross margin compression from 47% to 41% for the current reporting quarter was anticipated due to increased production coming from the lower margin veterinary medications line for which the Company recently received some product permits, and increased manufacturing overhead as we successfully completed our Huxian vaccine plant construction. We expect for manufacturing to continue to scale up throughout the year in preparation for the majority of Skystar's sales coming after the first quarter coinciding with China's celebration of the Lunar New Year holiday. Skystar expects a steady growth trajectory once all of its manufacturing plants can be completed and brought to full utilization rates," concluded Mr. Lu.

Financial Summary

For the year ended March 31, 2014, Skystar's revenues were roughly $6.8 million as compared to revenues of $5.5 million for the three months ended March 31, 2013, an increase of $1.3 million or 23.5%. Overall increase in revenue was due to increase in manufacturing at the Company's Huxian plant in combination with receiving product permits by the Ministry of Agriculture to manufacture select veterinary medications.

A breakdown of the year's revenue by production line is as follows:

- Revenue from sales of our veterinary medications increased by $1.4 million or 40.6%, from $3.4 million for the three months ended March 31, 2013 to $4.8 million for the three months ended March 31, 2014.

- Revenue from probiotic products decreased by $146,000 roughly or 8.8% from $1.7 million for the three months ended March 31, 2013 to $1.5 million for the three months ended March 31, 2014. The decrease was due to weak market demand for probiotics due to a decline in pork prices in the first quarter, which discouraged farmers from increasing their livestock farming.

- Revenue from feed additives increased by $44,000 or 15.5% from $286,000 for the three months ended March 31, 2013 to $330,000 for the three months ended March 31, 2014.

- Vaccine revenues increased by $5,000 or 4.1% from $131,000 for the three months ended March 31, 2013 to $136,000 for the three months ended March 31, 2014. Vaccine production is expected to commence production at Skystar's new facility during the second half of 2014.

Gross profit for the quarter was up $223,000 or 8.6% from $2.6 million for the three months ended March31, 2013 to $2.8 million for the three months ended March 31, 2014. Gross margin was 41.3%, down from 47% in the same year ago period. The decreased gross margin was mainly because the majority of our revenue during the year came from less profitable veterinary medications product lines.

Operating expenses for the quarter increased 8% to $1.6 million or 24% of total revenue, compared with $1.5 million for the same year ago period.

Research and development costs were insignificant for both the first quarter of 2014 and 2013 as there was no significant R&D effort undertaken during the first quarter because of the Chinese New Year. Research and development costs are expected to increase as new projects begin throughout the remainder of fiscal 2014.

Selling expenses totaled $370,000 for the three months ended March 31, 2014 as compared to $317,000 for the three months ended March 31, 2013, an increase of 16.5%.

General and administrative expenses totaled $1.3 million for the three months ended March 31, 2014 as compared to $1.2 million for the three months ended March 31, 2013, an increase 5.4%.

Operating income for March 31, 2014 was $1.2 million up $100,000 or 9.5% from the prior year. Operating margin was 17% versus 19% in the year ago period.

Net income for the quarter was $975,000 million or $0.13 per fully diluted share. This compares to net income of $713,000 or $0.09 per fully diluted share for the year ago period.

As of March 31, 2014, Skystar had approximately $6.9 million in cash, current assets of $88.4 million and total current liabilities of $23.7 million which resulted in net working capital of $64.7 million.

Mr. Lu concluded, "Skystar has reported a strong start to the fiscal 2014 reporting cycle. The Company believes that it has built a strong framework as the only U.S. listed animal pharmaceutical play in China. The completed and newly GMP certified manufacturing facility in Huxian gives Skystar the ability to produce veterinary medicines and vaccines utilizing modern batch processes, increasing production efficiencies and volume of product produced. More importantly, the Company has been able to launch and expand infrastructure within the tougher regulatory framework of China's new requirements for GMP production facilities. These modern manufacturing standards and rules help to ensure the safety of China's food supply as agriculture and animal husbandry standards in China move towards modern standards and industrialization," concluded Mr. Lu.

Business Outlook
Skystar currently maintains business outlook and anticipates delivering an 8% to 18% year over year increase in top line revenue for fiscal 2014 as compared to the prior year. The expected revenue range is $46 million to $50 million with gross margin of roughly 50% for fiscal 2014.

Conference Call Information
The Company will host a conference call on Friday, May 16, 2014 to discuss its financial results for the year ended March 31, 2014. Skystar's conference call will begin promptly at 7:45 a.m. EST to review first quarter fiscal 2014 financial and operational performance. Mr. Weibing Lu, Skystar's chairman and chief executive officer, will host the call, which will be webcast live.

Webcast will be made available on the investor relations section of the Skystar corporate website at http://www.investorcalendar.com/IC/CEPage.asp?ID=172772.

Phone dial-in to the conference call will be available in North America by dialing +1 (877) 407-8031 or internationally by dialing +1 (201) 689-8031.

An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853 or, when calling internationally, dial +1 (201) 612-7415, referencing conference ID # 13582730.

To be added to the Company's email distribution for future news releases, please send your request to [email protected].

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

Financial Statements

            SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
         CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
             FOR THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
                                (Unaudited)

                                                     Three Months Ended
                                                         March 31,
                                                ---------------------------
                                                    2014           2013
                                                ------------   ------------

REVENUE, net                                   $   6,832,588  $   5,530,741

COST OF REVENUE                                    4,009,403      2,930,886
                                                ------------   ------------

GROSS PROFIT                                       2,823,185      2,599,855
                                                ------------   ------------

OPERATING EXPENSES:
  Research and development costs                       4,213            461
  Selling expenses                                   370,208        317,836
  General and administrative expenses              1,276,417      1,211,273
                                                ------------   ------------
    Total operating expenses                       1,650,838      1,529,570
                                                ------------   ------------

INCOME FROM OPERATIONS                             1,172,347      1,070,285
                                                ------------   ------------

OTHER INCOME (EXPENSE):
  Other income (expense), net                        154,919           (187)
  Interest income                                    170,665        148,845
  Interest expense                                   (75,934)      (189,392)
  Change in fair value of purchase option
   liability                                         (16,520)         4,466
                                                ------------   ------------
    Total other income (expense), net                233,130        (36,268)
                                                ------------   ------------

INCOME BEFORE PROVISION FOR INCOME TAXES           1,405,477      1,034,017

PROVISION FOR INCOME TAXES                           430,027        321,284
                                                ------------   ------------

NET INCOME                                           975,450        712,733

OTHER COMPREHENSIVE INCOME :
  Foreign currency translation adjustment           (966,949)       550,883
                                                ------------   ------------

COMPREHENSIVE INCOME                           $       8,501  $   1,263,616
                                                ============   ============

EARNINGS PER SHARE:
  Basic                                        $        0.13  $        0.09
                                                ============   ============
  Diluted                                      $        0.13  $        0.09
                                                ============   ============

WEIGHTED AVERAGE NUMBER OF COMMON SHARES:
  Basic                                            7,676,268      7,613,712
                                                ============   ============
  Diluted                                          7,700,734      7,613,712
                                                ============   ============



             SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
                    CONDENSED CONSOLIDATED BALANCE SHEETS

                                   ASSETS
                                                    March 31,   December 31,
                                                      2014          2013
                                                   (Unaudited)
                                                  ------------  ------------

CURRENT ASSETS:
  Cash                                           $   6,848,905 $   8,142,296
  Accounts receivable, net of allowance for
   doubtful accounts of $960,578 (Unaudited) and
   $602,243 as of March 31, 2014 and December
   31, 2013, respectively                           12,663,549    11,009,498
  Inventories                                       25,265,783    25,903,586
  Deposits, prepaid expenses and other
   receivables                                       1,608,405     2,134,163
  Prepayments to suppliers                          40,541,475    41,061,144
  Loans receivable                                   1,046,835             -
  Deferred tax assets                                  403,372       364,425
                                                  ------------  ------------
    Total current assets                            88,378,324    88,615,112
                                                  ------------  ------------

PROPERTY, PLANT AND EQUIPMENT, NET                  30,417,653    28,269,155

CONSTRUCTION-IN-PROGRESS                             6,470,772     9,284,947

OTHER ASSETS:
  Long-term prepayments                              4,592,751     4,633,614
  Long-term prepayments for acquisitions                     -       183,344
  Intangible assets, net                             5,130,454     5,237,255
                                                  ------------  ------------
    Total other assets                               9,723,205    10,054,213
                                                  ------------  ------------
      Total assets                               $ 134,989,954 $ 136,223,427
                                                  ============  ============

                    LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable                               $   4,615,614 $   3,303,531
  Other payables and accrued expenses                6,551,419     6,467,605
  Short-term loans                                   5,680,500    10,640,500
  Deposits from customers                            1,991,907     1,877,211
  Taxes payable                                      2,852,844     1,315,486
  Due to related parties                             1,962,238     1,361,548
                                                  ------------  ------------
    Total current liabilities                       23,654,522    24,965,881
                                                  ------------  ------------

OTHER LIABILITIES:
  Deferred government grant                            795,270       802,130
  Purchase option liability                             78,960        62,440
                                                  ------------  ------------
    Total other liabilities                            874,230       864,570
                                                  ------------  ------------
      Total liabilities                             24,528,752    25,830,451
                                                  ------------  ------------

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY
  Preferred stock, $0.001 par value, 50,000,000
   shares authorized, No Series "A" shares
   authorized, 48,000,000 Series B shares
   authorized. No Series "B" shares issued and
   outstanding                                               -             -
  Common stock, $0.001 par value, 40,000,000
   shares authorized, 7,604,800 shares issued
   and outstanding as of March 31,2014
   (Unaudited) and December 31, 2013                     7,605         7,605
  Paid-in capital                                   37,690,867    37,631,142
  Statutory reserves                                 5,952,692     5,952,692
  Retained earnings                                 55,965,604    54,990,154
  Accumulated other comprehensive income            10,844,434    11,811,383
                                                  ------------  ------------
      Total shareholders' equity                   110,461,202   110,392,976
                                                  ------------  ------------
        Total liabilities and shareholders'
         equity                                  $ 134,989,954 $ 136,223,427
                                                  ============  ============



            SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
             FOR THE THREE MONTHS ENDED MARCH 31,2014 AND 2013
                                (Unaudited)

                                                     Three Months Ended
                                                         March 31,
                                                ---------------------------
                                                    2014           2013
                                                ------------   ------------
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net income                                   $     975,450  $     712,733
  Adjustments to reconcile net income to net
   cash (used in) provided by operating
   activities:
      Depreciation                                   400,291        313,561
      Amortization                                    62,477         60,872
      Provision for doubtful accounts                366,218        351,534
      Share based compensation                        59,725          4,340
      Change in fair value of purchase option
       liability                                      16,520         (4,466)
      Deferred tax assets                            (42,380)             -
    Change in operating assets and liabilities
      Accounts receivable                         (2,127,566)    (1,725,889)
      Inventories                                    419,398       (557,269)
      Deposits, prepaid expenses and other
       receivables                                   513,005        292,476
      Prepayments to suppliers                       169,771     (9,696,136)
      Accounts payable                             1,350,410      1,023,288
      Other payables and accrued expenses            135,167       (339,030)
      Deferred government grants                           -       (159,320)
      Deposits from customers                        131,733         28,061
      Taxes payable                                1,560,250       (288,655)
      Due to related parties                         606,813        201,325
                                                ------------   ------------
        Net cash provided by (used in)
         operating activities                      4,597,282     (9,782,575)
                                                ------------   ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
  Refund of long-term prepayments                    184,387              -
  Loans to third parties                          (1,054,704)             -
  Payments on construction-in-progress               (53,195)             -
                                                ------------   ------------
Net cash used in investing activities               (923,512)             -
                                                ------------   ------------

CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from short-term loans                           -      4,779,600
  Repayment of short-term loans                   (4,905,600)    (2,389,800)
                                                ------------   ------------
  Net cash (used in) provided by financing
   activities                                     (4,905,600)     2,389,800
                                                ------------   ------------

EFFECT OF EXCHANGE RATE CHANGES ON CASH              (61,561)        50,421
                                                ------------   ------------

DECREASE IN CASH                                  (1,293,391)    (7,342,354)

CASH, beginning of period                          8,142,296     11,321,848
                                                ------------   ------------

CASH, end of period                            $   6,848,905  $   3,979,494
                                                ============   ============

SUPPLEMENTAL DISCLOSURE OF CASH FLOW
 INFORMATION:
  Cash paid for income tax                     $           -  $           -
                                                ============   ============
  Cash paid for interest                       $     129,129  $     181,426
                                                ============   ============
  Non-cash investing activities
  Construction-in-progress transferred to
   property, plant and equipment               $   2,787,566  $           -
                                                ============   ============



             SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES
          CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
                  FOR THE THREE MONTHS ENDED MARCH 31,2014
                                 (Unaudited)



                          Common stock
                       ------------------    Paid-in
                         Shares    Amount    capital
                       ----------  ------  ----------
BALANCE,January 1,
 2014                   7,604,800 $ 7,605 $37,631,142

Foreign currency
 translation                    -       -           -
Share-based
 compensation                   -       -      59,725
Net income                      -       -           -
                       ----------  ------  ----------

BALANCE, March 31,
 2014                   7,604,800 $ 7,605 $37,690,867
                       ==========  ======  ==========


                            Retained earnings     Accumulated
                        ------------------------     other
                         Statutory                comprehensive
                         reserves   Unrestricted     income        Total
                        ----------  ------------  -----------   -----------
BALANCE,January 1,
 2014                  $ 5,952,692 $  54,990,154 $ 11,811,383  $110,392,976

Foreign currency
 translation                     -             -     (966,949)     (966,949)
Share-based
 compensation                    -             -            -        59,725
Net income                               975,450            -       975,450
                        ----------  ------------  -----------   -----------

BALANCE, March 31,
 2014                  $ 5,952,692 $  55,965,604 $ 10,844,434  $110,461,202
                        ==========  ============  ===========   ===========

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and include, without limitation, the Company's financial projections, and revenue guidance, expectations relating to scaling up of the production and the plant production capabilities, statements relating to the timing of various regulatory certifications, or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results.

Contacts:

Skystar Bio-Pharmaceutical Company
Scott Cramer
Director - Corporate Development & U.S. Representative
(407) 645-4433

Grayling
Investor Relations
Christopher Chu
(908) 251-9869
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Digital transformation is changing the face of business. The IDC predicts that enterprises will commit to a massive new scale of digital transformation, to stake out leadership positions in the "digital transformation economy." Accordingly, attendees at the upcoming Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA, Oct 31-Nov 2, will find fresh new content in a new track called Enterprise Cloud & Digital Transformation.
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp emp...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, will discuss how given the magnitude of today's applicati...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TAZMO technology and development capabilities in the semiconductor and LCD-related manufacturing fields are among the best worldwide. For more information, visit https://www.tazmo.co.jp/en/.